FDA Clears Latest Version of Mobile Imaging App
The U.S. Food and Drug Administration has cleared the new version of MIM Software’s mobile imaging app, which is now approved for diagnostic X-ray and ultrasound viewing, the company announced.
The U.S. Food and Drug Administration has cleared the new version of MIM Software’s mobile imaging app, which is now approved for diagnostic X-ray and ultrasound viewing, the company annouced.
Mobile MIM is also cleared for radiation treatment plan review and approval, the company said. Mobile MIM received FDA 510(k) clearance in February 2011, becoming the first diagnostic radiology app approved for viewing images and medical diagnoses based on CT, MRI, and nuclear medical technology.
Jerimy Brockway, software director at MIM, called the addition of viewing X-ray on a handheld device “a milestone for mobile health.” Mobile MIM can display images of more than 25 megapixels.
Mobile MIM is a thick client that brings the data to the device for fast manipulation independent of network performance, according to the company. Device-level hardware encryption provides security for HIPAA compliance, and users can remove data from the device after viewing.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
